Oregon Immunologist: "Alternative Biological Concept World" Lacks Scientific Credibility
Susan Norcross to Direct BioResource Education Programs
BioResource Plans Saturday Product Training Seminars in 2002
The Development of PEKANA's Unique Homeopathic-Spagyric Processing Method
New PEKANA Medications Now Available
A Brief History of Bacterial and Fungal Isopathic-Homeopathic Remedies
Historical Timeline
What Practitioners Need to Know About Enderlein’s Theory & Isopathic-Homeopathic Therapy
Clinical Survey Results Show 99% of Doctors Find SulfRedox Mineral Supplement Highly Effective
Questions and Answers
Biotalk
Hunting Down Stealth Pathogens

Oregon Immunologist: "Alternative Biological Concept World" Lacks Scientific Credibility

Says Clinging to Outdated Pleomorphic Theories Diverts Attention from the True Value of Isopathy; Suggests Proper Clinical Studies May Reveal Isopathic Therapy's Ability to Break Immunological Unresponsiveness

Calling for health care professionals to "be more open-minded" and "pursue scientific truth" when evaluating microbial and non-microbial forms in the blood, immunologist Gitte S. Jensen spoke spiritedly last October during her presentation at the BioResource Annual Seminar held in San Jose, California. Dr. Jensen, who directs the Holger NIS research group in Ashland, Oregon, also stressed that patients are "seeking real help" in their fight against chronic illness. She urged mainstream and alternative practitioners to "discover better answers based on modern research" instead of clashing over outdated theories.

"Researchers, microscopists, medical doctors and practitioners all must work toward a greater recognition of the involvement of microbes in chronic illness, but it cannot be based on the need to believe in an alternative biological concept world, such as that proposed by Enderlein," emphasized Dr. Jensen, an international lecturer who received her Ph.D. in Immunology from the University of Aarhus, Denmark in 1986. "That world does not exist as a viable entity. Instead, science needs to carefully identify each particle that microscopists see in the blood and verify what biological process went wrong to create the different forms."

Dr. Jensen, who formerly served as assistant professor in the Department of Surgery at McGill University in Montreal, became interested in live blood research nearly seven years ago when she took Darkfield training, but came away highly skeptical.

"I was told that white, bubble-like forms in the live blood were Candida, but after intensively studying samples I realized this was simply not true," she noted. "This phenomena is actually due to membranes breaking down and taking on different shapes. After that experience, I wanted to move blood examination beyond the study of shapes using Darkfield microscopy alone by employing contemporary techniques for studying sub-cellular particles."

Trained in mainstream science, the Oregon immunologist declared that "it is dogma for me that all living things must contain DNA until I can see logical sense otherwise." She cautioned that even though blood morphology can provide value as a health status indicator, simply viewing a blood form under a microscope is not enough to identify pathogens.

"Shapes can confuse and mislead on their own," Dr. Jensen said. "Many factors contribute to the formation of shapes, plus similar shapes can be derived in different ways. We need to know conclusively when we are viewing Heinz bodies caused by the polymerization of hemoglobin, when we are seeing fibrin, and when we are looking at chains of viruses or microbes. We also need to verify that those microbes are contributing to clinical problems and not just riding along innocuously. As a result, the observer must stain the form, check for DNA, and correctly link each familiar shape with its actual intent in the blood."

INVESTIGATING BREAKDOWN PRODUCTS
For the past several years, Dr. Jensen's research team has investigated breakdown products of red blood cells, white blood cells and platelets, as well as how these forms can be linked to patient treatment strategies. Many diverse factors are responsible for this destruction process, including cell membrane stability, oxidative damage, essential fatty acid status, cholesterol related to hormonal balance, protein digestion and toxic load.

"It's important to understand that if a piece of red cell membrane becomes unstable and starts to break down, it does not simply dissolve in the plasma," said Dr. Jensen, who served as chairperson for two International Symposia on Pleomorphic Microbes in Health and Disease. "As it disintegrates into particles, the lipid bi-layer will always segregate from the plasma, often by rounding up and creating a bubble."

This process occurs because biological membranes have integral coatings made of proteins, cholesterol and other molecules that, along with serum factors such as vitamins, determine the folding and appearance of breakdown products. Dr. Jensen further noted that it is common to see transient bacteria, which most likely enter the blood through the mouth or intestines, along with other particles.

"Darkfield microscopists also need to be aware that it's not surprising to see breakdown products from leukocytes right out of the finger as the cells die rapidly on the slide," she explained. "Therefore, when viewing live blood, it is essential for the observer to know whether he or she is looking at pieces of an erythrocyte, a leukocyte or an actual microbe because bits of membrane from different sources may create different shapes. After all, the primary goal is to benefit patients by assessing microbes and discovering the true origins of clinical problems."

With misinformation being circulated about so-called pleomorphic life cycles, microscopists certainly must become aware of the substantial limitations of Darkfield as a diagnostic tool. On the other hand, Dr. Jensen emphasized that mainstream methods of culturing microbes, such as a throat swab, or using genetic technology also have severe shortcomings.

"It's an area where mainstream medicine goes wrong because it misses so much of the overall picture," Dr. Jensen declared. "For example, basic soil science has revealed that we can only culture approximately 0.4% of all the microbes that exist, which barely begins to scratch the surface. And we have the arrogance to think that we can culture everything that comes out of our bodies? When it comes to studying the blood and understanding the role of microbes in chronic disease, we have a long way to go."

MICROBIAL FORMS IDENTIFIED
Although Dr. Jensen believes that medical science still has much work to do, a number of research groups have begun correctly identifying various particles routinely seen in live blood analysis. For example, highly sophisticated Proteom analysis conducted by Dr. Christopher Gerner, assistant professor of Biochemistry at the University of Vienna, Austria, has linked specific blood forms to oxidative damage and other normal body processes. In addition, Dr. Jensen's research team has identified microbes that can hide out in the red blood cells, and also discovered an uncharacterized microbe not described in gene banks that may be aligned to alpha-proteo bacteria.

"We have identified a microbial presence in patients that can enter the red blood cells and take up quite a bit of volume," she said. "It is aerobic, and prefers to grow in environment where human cells would feel there is an oxygen deficiency. However, I am aware of data that compares this particular bug to mycoplasma, so we need to investigate further. But an even more important point is that medical professionals must recognize that humans have an incredible potential for harboring multitudes of different microbes, and that we are blinding ourselves with our diagnostic tools by only looking in certain directions. We all simply need to be much more open-minded."

TURNING A BLIND EYE TO BUGS
According to Dr. Jensen, mainstream science has documented that microbes can use molecular mimicry - where a bug mimics the body's own molecules - to confuse the immune system. This process can lead either to autoimmune disease or immunological anergy, a state where immune cells no longer respond to certain families of microbes. She made clear that anergy does not involve a general down-regulation or reduced production of immune cells, but a condition where certain shapes are no longer recognized and responded to as invaders, enabling them to take advantage of the host.

"The immune system works by recognizing shapes and then reacting to foreign invaders, but if a 'bug' happens to be in the wrong company or dose at the wrong time, the cytoplasmic machinery can actually shut down toward it," Dr. Jensen explained. "For example, our standard Immunoglobulin Y-shaped molecule has two receptor sites that recognize foreign antigens and trigger a reaction. If a certain shape or foreign body has been presented without enough strength or if the patient has a poor nutritional status, extensive oxidative damage or too many inflammatory mediators, it's possible that the immune system can fail to respond and actually turn off toward that particular shape. The result is anergy instead of an aggressive immunological response."

Once this pacification occurs, Dr. Jensen explained that microbes can seek out hiding places, such as in the red blood cells, prostate and colon, and compete for nutrients, or perhaps produce toxins that suppress the immune system. Her research indicates that patients who suffer from severe chronic illnesses may be victims of immunological anergy.

"We conducted a pilot study (see sidebar) of patients with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS) whose blood showed no obvious change in morphology when viewed using Darkfield microscopy, and who produced no infectious disease microbes that could be cultured by mainstream diagnostic methods," she said. "Yet even after we purified the red blood cells by repeated washing, we could actually identify motile bacterial forms using DNA staining technology. In fact, the cultures of red blood cells practically resembled a zoo or flea circus. Surprisingly, the patients had three different mainstream medical diagnoses, were born and raised on three separate continents and represented three different racial groups."

Dr. Jensen indicated that these bacterial forms might affect the delivery of oxygen, secrete toxins or compete for host nutrients. Moreover, they could perhaps suppress the immune system through molecular mimicry, creating an opportunity for a family of bugs to thrive.

"If microbes can grow in red blood cells, this presence may even reach to the bone marrow where our cells are produced," Dr. Jensen noted. "If certain bugs are metabolically active, they can be expected to compete with the patient for certain minerals and amino acids, which could lead to clinical depression, for example."

RESOLVING IMMUNOLOGICAL ANERGY
Fortunately, anergy is often a transient process, which means that the immune response can be re-activated. Dr. Jensen indicated that modern isopathic bacterial therapy may provide a solution to this important but often overlooked problem by "knocking the immune system out of an anergic state" and getting it back on track.

"Isopathics offer something different," she noted. "We need to look scientifically at how these remedies work because they may very well contain what immunologists call 'super-antigens.' These are molecules from microbes that have the ability to link our immune cells and stimulate a potent reaction, all without having to be recognized specifically by a limited clone of immune cells."

By linking the outside regions of immune cell receptors, a specific molecule could have the potential to stimulate up to five percent of all T-cells in the body, not merely a few cells that would recognize a particular shape. This capability would result in a much broader immune response vital to reversing anergy.

"I also would agree that an isopathic remedy made from metabolic products of a bacteria would be preferred over those made from cell wall fragments," Dr. Jensen emphasized. "This distinction is significant because cell wall antigenic material can overly stimulate the immune system and lead to harsh inflammatory reactions"

Nevertheless, the pleomorphic pioneer strongly asserted that mainstream medicine would continue to ignore isopathic therapy unless biological medicine proponents start using proper scientific vocabulary and conduct valid clinical studies.

"We can learn from each other," she said. "In general, modern medicine is not applying anergy testing to the majority of patients with chronic illnesses. They have not looked at whether these people have a broad ability to respond to antigens they are presented with, or whether their immune systems have started shutting down toward specific microbes, such as streptococcus or fungi. In the past, anergy testing was used prior to major surgery to make sure the patient had a strong immune system with a broad response. It was also used for many years in monitoring HIV patients to see when the immune system starts to shut down toward certain antigens. Unfortunately, anergy testing is not in wide use at the present time. Overall, I believe science needs better techniques to get an understanding of anergy. A large number of people suffer with either long-term or transient anergy. Apart from some nutritional and stress-management strategies, isopathics may offer help to resolve this problem."

LOOKING TOWARD THE FUTURE
Stressing the need for more good science, Dr. Jensen noted that her research team has developed a test kit to help identify microbial load in human blood and evaluate microbial presence in cellular and sub-cellular particles.

"The test enables a practitioner to determine if patients have microbial parasites in their red blood cells, and whether they may need a more specific test for Lyme's disease, Candida infection, mycoplasma or some other condition," she said. "It represents a preliminary step toward a more specific diagnosis of microbes that may be latent, cell wall deficient or hiding in the erythrocytes."

Dr. Jensen also pointed out that mainstream microbiology has come a long way the last several years, citing that researchers have published original research in peer-reviewed scientific journals on obscure microbes and their contribution to chronic illness.

"We still have many questions," she concluded, "and more research work needs to be done to discover the answers to acute and chronic illnesses."

Susan Norcross to Direct BioResource Education Programs

Susan Norcross B.S., R.N., L.Ac., has agreed to direct BioResource's education programs. Beginning in January 2002, her responsibilities will include creating educational materials, speaking at schools that emphasize alternative therapies, directing product-training seminars and representing BioResource at national conferences and trade shows.

A respected, knowledgeable practitioner and ardent proponent of German biological medicine, Norcross has used alternative therapies in her busy clinical practice for the past 12 years. She will join the BioResource staff while continuing to see patients at her St. Louis, Missouri office.

"The medications offered by BioResource represent the elite of natural, biological German therapeutics," Norcross said. "They are uniquely dynamic and powerfully effective healing agents that have produced dramatic results over the years, both in my own practice and in those of many colleagues. Centuries of German research and empirical practice have created a wealth of healing wisdom along with a host of potent natural therapies. During my trips to Germany, I have been deeply impressed with the excellence of the information and superiority of the remedies.

"The continuing effort by BioResource to expand this knowledge base through seminars, literature, and funding for scientific research - as well as by providing high quality remedies - is a great benefit to both practitioner and patient," she added. "I am pleased to contribute to the further dissemination of this critical body of knowledge in my role as director of education."

Acknowledgements

EDITOR: Mike Sheehan - PRODUCTION: JB Communications, Santa Rosa, California
Please send comments to: bioresource3@prodigy.net

BioResource Staff

PRESIDENT/ DIRECTOR OF MARKETING Mike Sheehan - DIRECTOR OF SHIPPING Terry Sheehan - DIRECTOR OF SALES Lou Goring - SALES ASSISTANT Patricia Sheehan - SHIPPING ASSISTANT David Bickel - ADMINISTRATIVE ASSISTANT Pamela Bickel - DIRECTOR OF EDUCATION Susan Norcross L.Ac., R.N. - PRACTITIONER SUPPORT Rain Olympia Crow D.C., N.D.

SEMINAR SPEAKERS

Rain Olympia Crow D.C., N.D. - Gary Klepper D.C., N.D. - Justine Anderson D.C., N.D., A.T., C. - Bart Stark D.C., DIBAK, DIAMA

BioResource Plans Saturday Product Training Seminars in 2002

In addition to its major seminars held in Colorado and California, BioResource has scheduled producttraining sessions on seven Saturdays during 2002 for practitioners who wish to learn more about German biological medicine.

Taught by Bart Stark D.C., DIBAK, DIAMA or Justine Anderson D.C., N.D., A.T.C., the one-day events will include a discussion of PEKANA homeopathic-spagyric medications, SanPharma isopathic remedies, protocols , clinical results, applied kinesiology and case management.

The Seminar Schedule for 2002 is as follows:
Saturday, January 26 Scottsdale, AZ 9 am to 5 pm (Team)
Saturday, March 2 Dallas, TX 9 am to 5 pm (Stark) 
Saturday, March 23 Denver, CO 9 am to 5 pm (Anderson)
Saturday, April 6 Atlanta, GA 9 am to 5 pm (Stark)
Saturday, May 11 Portland, OR 9 am to 5 pm (Anderson)
Saturday, September 14 New York 9 am to 5 pm (Stark)
Saturday, October (Date TBA) 9 am to 5 pm (TBA)

BioResource's Annual multi-day training seminar - taught primarily by Rain Olympia Crow D.C., N.D. and Gary Klepper D.C., N.D. - will take place April 25-28, 2002 in Boulder, Colorado.

A second multi-day seminar is tentatively scheduled for the San Francisco Bay Area in September 2002.

To register for a seminar or receive more information, please contact: BioResource at 800/203-3775 or send an email to bioresource3@prodigy.net

The Development of PEKANA's Unique Homeopathic-Spagyric Processing Method
By Dr. Peter Beyersdorff, Founder and President, PEKANA Naturheilmittel Copyright Dr Peter Beyersdorff, 2001

The reason I developed the unique PEKANA homeopathic spagyric production method was that I wanted to produce the most energetic and effective remedies available, and also potentially save spagyrics. These wonderful medications that the great 16th Century medical reformer and physician Paracelsus (1493-1541) had extensively written about were in danger of disappearing forever. Since the early 1980s, Biological Medicine in Germany had been under immense pressure by the pharmaceutical industry and government agencies, which wanted to see biological medications disappear from the market for obvious reasons.

In addition, some influential and intolerant homeopathic physicians were fixated on Hahnemann and homeopathy. They wanted spagyrics excluded from the German Homeopathic Pharmacopoeia (HAB), which is the prerequisite for producing remedies in Germany. These were terrible times for Biological Medicine and it was completely unresolved as to what the final outcome would be. In recent times, the German public has become more aware that chemical drugs do not heal illnesses, but rather burden the body. As a result, a steadily growing number of people do not want to take pharmaceutical drugs to treat illnesses.

Although other spagyric production methods were available at the time of my decision in 1985, I felt those techniques could not pass the close scrutiny of scientific analysis methods used by the German authorities. I also realized that permission to produce spagyric remedies could be revoked at some future date if the production criteria became more stringent. For this reason, I decided to produce spagyric remedies in a modern, scientific and verifiable manner.

Fortunately, the German Food and Drug Administration (BGA) employed individuals who were supportive of my spagyric production method. I was given the opportunity to present and explain my unique method, and this led to acceptance and listing in the First Official German Homeopathic Pharmacopoeia (HAB) in 1991. This was an important breakthrough because, as I mentioned previously, remedies can only be produced today in Germany if they are listed in this book.

Other spagyric methods are also currently listed, but I am really curious as to how long they will remain in the HAB. The old production methods all have the same mistakes. The remedies are distilled and contain their information i n a high percentage of ethanol. Or they skip the important step of incineration and therefore fail to extract essential minerals that are captured in the PEKANA production process. After all, this is the whole basis of spagyrics, and led me to develop my own methods. We know today that minerals are a considerable part of the high efficacy of the individual spagyric remedy parts. These are combined in the PEKANA complex remedies.

Moreover, the alcohol percentage of a spagyric remedy is important. In the traditional spagyric production method, the mother tinctures are distilled and often contain up to 80% ethanol, while PEKANA tinctures are only about 20%, so the total percentage of ethanol that comes from the "normal" homeopathic tinctures is considerably decreased. As a result, the greater the spagyric parts of a remedy, the less ethanol contained in the final product.

Finally, it is important to point out that all parts of a preparation cannot be made using the spagyric method. Strong antibiotic herbs, for example, destroy the yeast needed for fermentation, while minerals or metal salts such as Ferrum phosphoricum must be produced homeopathically because they cannot be processed spagyrically.

THE IMPORTANCE OF HAND SUCCUSSION

The additional step of succussing, or potentizing, the PEKANA spagyric mother tincture makes the plant substance even more "noble, pure, dynamic or energetic" in the Hermetic tradition. In this vital and creative act, the energy inherent in humanity, and specifically in the individual involved in the act of hand succussion, is given to the remedy in the form of vibrational information. The material is then homeopathically potentized, making it even more energetic. In addition, the inherent but latent curative power of the substance is stimulated and becomes active, thereby reaching a higher quality. As a result, the concentrated energy allows unparalleled healing efficacy at the physical, mental and spiritual levels.

It also is important in energetic medicine to take a close look at the quality of the people making and handling products because they will determine the quality of the remedies. I think it's true that medications can only be as good as their producers. Therefore, PEKANA strongly believes that the highest quality, most energetic remedies can be made only by ethical, moral people at every level of production. These personal standards, as well as meticulous care, are mirrored in the products.

Adding inherent human energy by hand succussion allows a substance to develop or unfold its total potential energy. It is a uniquely creative act that dramatically increases the energy of the remedy, and for this reason it is impossible for machines to do. That's why at PEKANA succussion is always done by hand.

PEKANA PRODUCTION FACTS

PEKANA's total production method is Good Manufacturing Practices (GMP)-certified according to WHO and European Community rules. The medications meet the highest production standards for quality, safety and efficacy.

PEKANA only uses the specific parts of either fresh or dried herbs prescribed in the Homeopathic Pharmacopoeia. All plants are analyzed and standardized so that product quality remains constantly high.

PEKANA uses fermentation to achieve a pure, carefully processed mother tincture containing a plant's own alcohol, whereby the inherent vital energy is absorbed. The plant-specific minerals extracted from the ashes are purified and added to the mother tinctures.

EKANAavoids any form of distillation to keep the effective substances intact, and ensure that biocatalysts (enzymes) and vitamins are not destroyed. In contrast, some spagyric companies distill the plant residue using 80% ethanol or more, which harms the energy content (as can be confirmed in thin-layer chromatography photos).

EKANA verifies the energy of the extracted active substances and inspects the pharmaceutical quality of every mother tincture by means of comparative chromatography. Only those spagyric preparations with matching or superior formation of energetic zones than the corresponding homeopathic are used in further manufacturing steps.

EKANA's spagyric manufacturing process achieves a low ethanol rate compared to other homeopathic or spagyrics remedies.

PEKANA medications are hand-succussed, which is essential to maintain vital energy, and potentized according to the rules and regulations of the Homeopathic Pharmacopoeia.

New PEKANA Medications Now Available

BioResource has added five PEKANA homeopathic- spagyric medications to its growing product line, making a total of 52 PEKANA remedies now available in the U.S. These new medications are:

CITRIPLUS CITRIC ACID - For proper acidbase balance and energy enhancement
DEMYC TOPICAL DROPS - For skin, hair and nail fungus
FORMIPLUS FORMIC ACID - For arthritic and rheumatic conditions, and treatment of allergies
INFLAMYAR SPAGYRIC OINTMENT - For sports injuries, sprains, bruises, joint problems, muscle strains and acute and chronic inflammation
RADINEX SPAGYRIC DROPS - For defending the body against the debilitating effects of radiation and "electro-stress." This versatile remedy also promotes the excretion of biologically incompatible electromagnetic frequencies (EMFs) from the connective tissue matrix, including those caused by exposure to cell phones, computers, power lines and other sources.

The CitriPlus, FormiPlus and RADINEX are available in 100 ml oral drops, while the DEMYC external drops come in 20 ml bottles. The INFLAMYAR topical spagyric ointment is packaged in 100 gram tubes.

A Brief History of Bacterial and Fungal Isopathic-Homeopathic Remedies
By Peter Gosch Copyright, Peter Gosch, 2001

In 1990, the work of Professor Dr. Guenther Enderlein was introduced to medical practitioners and the general public in the United States through the book Hidden Killers, which I co-authored. For many years, Professor Enderlein's extensive, yet controversial research was ignored by the established medical and scientific community. His frustration about this fact is clearly reflected in his later writings. Nevertheless, the fundamental idea that serves as the basis for Professor Enderlein's work is absolutely correct: diseases need to be addressed with natural therapies and not with chemical drugs.

But why was his work not accepted by mainstream medicine? During the years preceding and following publication of Hidden Killers, I researched the life and work of Professor Enderlein, but always found one aspect disturbing. After diligent investigation, I was unable to locate anyone who could clearly explain and verify Enderlein's theories of supposed microbial life cycles in light of the latest scientific research. On the contrary, I was amazed to discover that his work had almost become a type of cult among some individuals, and a matter of dogma to accept it at face value. Perhaps as amazing, modern research using the latest scientific tools and techniques to attempt to confirm Enderlein's work had not been actively pursued by European lecturers and others who taught these theories.

Within this group, I discovered that to question the validity and usefulness of darkfield microscopy as a diagnostic tool was akin to heresy. Moreover, questions were ignored concerning why Enderlein's proposed life cycle of the fungus Mucor racemosus Fresen could not be confirmed by the scientific community. To request proof that proposed lower, benign microbial forms - called regulators by Enderlein and supposedly contained in his remedies - actually copulate with so-called highly developed, pathogenic forms and break them down was often met with indignation and disdain.

However, the current, simplistic explanation of how Enderlein-based isopathic-homeopathic fungal remedies work completely ignores exhaustive research in the field of immunology and microbiology conducted over the past decades. If Enderlein's work is correct and invaluable, then it must also be able to pass close scrutiny by all the modern, molecular level, scientific methods available. Proponents of biological medicine should welcome close scientific investigation because this may help practitioners use powerful isopathic remedies even more effectively. In addition, it can help these remedies gain wider acceptance in the mainstream medical community.

Dr. Otto Schmidt's Mucor Remedy

It has been assumed for decades that the ideas and remedies of Enderlein were unique. This is due to the fact that information to the contrary has not been widely available. However, it is important to emphasize that the last decade of the 19th and first decades of the 20th century were the Golden Age of German medicine. During this period, German-speaking Europe was a beehive of activity, and a hotbed of new and exciting scientific ideas and research. This is reflected by the numerous German researchers who were awarded prestigious Nobel Prizes for outstanding scientific achievement during the first two decades of the 20th century.

Prof. Dr. Enderlein certainly benefited from the work of the numerous researchers of this time. For example, the German chemist Wilhlem Ostwald, who received the Nobel Prize for Chemistry in 1909, was one of the young E n d e r l e i n 's chemistry teachers. Over the past several years, I have found German-language texts by medical practitioners and researchers that have filled in some of the gaps in this area.

In this article, I would like to present information on how other researchers had historical precedence over Enderlein in several areas. Already in 1901, Dr. Otto Schmidt cultured and produced his isopathic therapy f rom the fungus Mucor racemosus Fresen (He extracted the fungus from cancerous tissues and developed this into a remedy he called Antimeristem). In 1903, Professor Friedrich Friedmann produced an isopathic bacterial tuberculosis remedy from the bacteria found in the cold-blooded sea turtle Chelone corticata, the Mycobacterium chelone. The work of these important researchers and others was well-known to Enderlein.

Although Enderlein quotes the work of many researchers in his 1925 book The Life Cycle of Bacteria (Bakterien Cyclogenie), some lecturers who promote his concepts today have not given key scientists and doctors proper credit for the role they played in Enderlein's work. A number of these important individuals are briefly presented in this manuscript.

The Development of Isopathic Remedies Homeopathy

(Greek: homoion=similar, pathos=suff e r i n g or disease) is the medical art of treating illnesses with small doses of substances that have been diluted and upgraded to energetic remedies by the creative act of forcef u l l y shaking the dilution by hand, called succussion. Isopathy (Greek: iso=same, pathos=suffering) is the treatment of illnesses with the same substance that causes the illness, and therefore includes bacterial and fungal microbes.

In 1939 the German physician Karl Stauffer M.D. explained the fundamental difference between homeopathy and isopathy:

Homeopathy attempts to restore disrupted functions and life processes of the body that then is able to successfully eliminate diseases. Patients are prescribed a homeopathic substance that in large doses provokes symptoms in a healthy person similar to those exhibited by the ill patient. Homeopathic remedies are typically parts of herbs or minerals. Homeopathy does not address bacteria or other microbial pathogens and their toxins directly, but rather restores the internal terrain to a healthy state that is hostile to pathogens and promotes the healing process. (1)

Isopathy, on the other hand, directly addresses microbial pathogens or their toxins that cause damage to the body and cause illnesses. Isopathic-homeopathic remedies are homeopathically diluted and potentized. It is important to emphasize that these medications do not contain the actual active forms of the microbes, but stimulate the body to initiate a response to address pathogens and their toxins (2) present in the body that have been acquired through infection or heredity. The body is then able to address the underlying acute or chronic infection, or infestation, that it was not able to eliminate prior to treatment with the isopathichomeopathic remedy. The SanPharma isopathichomeopathic fungal remedies Aspergillus niger, Mucor racemosus, Penicillium notatum and Candida parapsilosis are examples of this category of medications.

Attempts to heal illnesses with isopathic-type remedies dates back to classical times and were advocated by Paracelsus (1493-1541), the great physician of the 16th century. Treatment with homeopathic as well as isopathichomeopathic remedies can be traced to the time of Samuel Hahnemann (1755-1843).

In the late 19th century famous bacteriologists such as Robert Koch (1843-1910) of Germany and Louis Pasteur (1822-1895) of France performed pioneering work in microbiology. The subsequent discovery of a wide variety of benign and pathogenic microbes and their toxins laid the groundwork for development of entirely new types of isopathic remedies, including bacterial and fungal medications. This had far-reaching implications, specifically in the field of cancer and tuberculosis research and therapy as scientists turned their attention toward finding a cure for these diseases.

For example, early 20th Century researchers and medical practitioners began to experiment with a wide variety of benign microbes, as well as pathogenic microbes and their toxins found in nature or in the serum of humans and animals. This led to revolutionary research in the field of biological medicine by such individuals as Professor Albert Adamkiewicz M.D., Professor Friedrich Friedmann M.D., D r. Otto Schmidt, Eugene Louis Doyen M.D., Antoine Nebel M.D., Dr. Wolfgang Schmidt and Professor Guenther Enderlein. These and other researchers focused on the role that microbes play in the development of diseases. They discovered that pathogenic microbes could be combated, and illnesses eliminated, using isopathic or isopathichomeopathic remedies.

Historical Timeline

1796 The era of homeopathy begins. Samuel Hahnemann's (1755-1843) work "Law of Similars" is published in Christoph Wilhelm Hufeland's M.D. (1762-1836) "Journal for Practical Medication Studies" in Germany. This proved to be a breakthrough in homeopathy and introduced the general public to the concept of Similia similibus curantur ( like is cured by like). (3)

1796 The era of conventional vaccinations begins. The Scottish physician Edward Jenner (1749-1823) inoculates a boy with the relatively harmless live cowpox matter taken from the lesions of a young dairymaid. This vaccination resulted in complete protection from the deadly smallpox and marks the beginning of universal vaccination in Western Medicine. (4)

Contemporary members of the European medical community accepted Jenner's research, however many had difficulty accepting homeopathy. This is all the more striking because the work of both had a common basis on one point; both used small quantities of a substance to treat patients. Whereas Hahnemann used homeopathically processed substances to treat diseases, Jenner inoculated with a minute amount of live cowpox to prevent the outbreak of smallpox, laying the foundation for modern vaccinations.

1823 - 1849 The German veterinarian Johan Joseph Wilhelm Lux (1776-1849) performs extensive research and treatment with isopathic remedies on animals. (5)

1870 The botanist G. Fresen first identified Mucor racemosus as a mold fungus. This fungus participates in decomposition processes, assisting the decay of animal and plant remains. The dead matter is converted into gases and minerals that can be recycled in other organisms.

1890 At the end of the 19th century the physician Professor Albert Adamkiewicz M.D., who practiced medicine in Vienna, Austria, was one of many researchers looking for a biological treatment for cancer tumors that would make surgery unnecessary. Professor Adamkiewicz was appalled by the fact that patients of the day who had undergone cancer surgery simply had terrible survival rates. He was of the opinion that cancer was caused by a microorganism, and felt the solution to the cancer problem needed to come from inside the body. His research brought him to the conclusion that the cancer itself held the key to healing this disease and this paved the way for his development of an anti-cancer remedy. (6)

Professor Adamkiewicz informed the Austro - Hungarian Royal Academy in Vienna that cancer was caused by a microorganism and could be treated by a remedy he developed called Cancroin, also spelled Kankroin, based on the concept of treating cancer with its own toxins. On June 6, 1890, he first informed the Royal Academy about the parasitic nature of the cancer cell and its toxicity. He treated the tumor with its own toxin by prescribing his reme d y. Adamkiewicz documented that his remedy could heal cancer patients who were considered incurably ill without surgery. He was convinced that Cancroin could stop the growth of cancer cells as well. In addition, Adamkiewicz was of the opinion that cancer could not be completely healed through surgery, chemotherapy or radiation treatment, and that these endanger the lives of the patients and may even kill them. He maintained that radium and x-rays only destroy cancer locally, and in the process destroy healthy as well as pathological tissues. (7)

Emil Schlegel M.D. (1852-1934) was indisputably the most important German homeopathic physician, researcher and writer during the first three decades of the 20th century. (8) In 1927, he wrote, "The idea of treating cancer with its own toxin was the idea of Adamkiewicz." (9) Dr. Schlegel went on to write that, "Based upon this hypothesis he developed an anti-cancer remedy. He called this medication Cancroin, the metabolic product of the cancer cell." (10)

1901 The era of isopathic-homeopathic fungal remedies begins. Dr. Otto Schmidt cultures and develops vaccines from the fungus Mucor racemosus Fresen. At the turn of the century, Dr. Schmidt was also seeking a remedy for treating tumors. He wrote that extraction of the cancer causal agent from a fully encapsulated tumor was the best method, and that the causal agent could then be cultured and processed. His idea was to create an isopathic medication that produced immunity against the cancer-causing pathogen. Dr. Schmidt extracted the fungus Mucor racemosus Fresen from cancerous tissues and developed this into a remedy he called Antimeristem. According to Emil Schlegel M.D., "The isopathic character of O. Schmidt's remedies is unquestionable." (11) Dr. Antoine Nebel agreed with Schmidt that the Mucor fungus must be a carrier of an infectious agent and stated, "It is the merit of Dr. Otto Schmidt to have found this (cancer) host in Mucor racemosus." (12)

Dr. Schmidt noted that there were still many questions open and that these needed to be answered with further research. For example, since various types of malignant tumors exist with different causal agents, he believed it was important to develop remedies from each different tumor.

The German oncologist Josef Issels M.D. (1907- 1998) was one of the best known holistic medical practitioners in the field of oncology in the second half of the 20th century. He wrote that "Of all the immunological possibilities for treating cancer, that method of treatment developed by Otto Schmidt (Cologne, Germany) stimulated the most interest among doctors and the public. Already in 1903 he was able to achieve the regression of cancerous tumors by immunological methods. In the years 1903 and 1905 he published in leading German and English publications his view and the results that he had achieved with his preparation "Antimeristem." In 1911 he reported in the Central Journal for Gynecology (Zentralblatt für Gynäkologie, Nr. 51) on the treatment of 304 cancer patients, the condition of 192 of these patients was improved by his therapy. In the case of 68 patients a complete remission of the tumor took place, of which 28 were permanently healed." (13)

1903 The era of isopathic-homeopathic bacterial remedies begins. Friedrich Friedmann (1876- 1953) discovered and isolated a non-pathogenic isopathic bacterial tuberculosis remedy from bacteria found in the cold-blooded sea turtle Chelone corticata (Mycobacterium chelonae) in 1903.

Friedmann later became professor for TB research at the University of Berlin. He came to the conclusion that his bacterial remedy protects against, and establishes immunity against TB like a vaccine, and heals mild, although not advanced cases of this disease. (14)

Friedmann had apparently found a way to treat and heal tuberculosis without requiring patients to undergo costly operations or long stays at hospitals and spas. By October 1912, nearly 1,500 people had been successfully treated with his biological isopathic remedy. In 1913 Dr. Friedmann accepted an invitation from the U.S. Senate to lecture on his discovery. Past U.S. President Theodore Roosevelt also wrote the following words to Dr. Friedmann on April 22, 1913: "With the heartiest good wishes for your continued success in your great work for mankind." (15)

Professor Friedmann wrote that several hundred ampules of his bacillus vaccine remedy were given as a present to a Dr.Wegner. These ampules served as the basis for the production of a similar remedy in 1934 by a company where Professor Guenther Enderlein served as head of production control. (16) The remedy produced under Enderlein's supervision became known as Mycobacterium phlei (similar to the Mycobactin S now produced by SanPharma). It should be noted however that Friedmann deserves credit for being the first to discover a benign isopathic-homeopathic bacterial remedy for treating various forms of TB, and that other researchers built their work and remedies on his extensive labors, including Professor Enderlein.

1903 The French physician Eugene Louis Doyen (1839- 1916), presented a remedy extracted from cancer cells. The German physician Josef Issels M.D. wrote, "The French surgeon Doyen successfully treated superficial tumors, later also other tumors with a remedy developed from the microbe he discovered, the "Micrococcus neoformans", in which he saw the cancer causal agent. With a vaccine from weakened cultures of this pathogen he was able to heal 42 of 242 mostly inoperable cancer cases, as he reported at the International Congress in Madrid in 1903." (17)

1910 The era of chemotherapy begins. Paul Erlich (1854-1915) and Sahachiro Hata (1873-1938) 
begin the age of chemotherapy with their tests on the drug arsphenamine. This form of treatment involves the application of chemical substances that have specific and toxic effects to a disease-causing microorganism. (18)

1915 Antoine Nebel M.D. (1860-1957), of Switzerland, confirms the work of Doyen and Schmidt and develops his own remedies. According to Josef Issels M.D., "From 1910 to 1920 Nebel reported on the treatment of incurable cancer patients with a vaccine, which is practically identical with the Schmidt vaccine." (19)

1925 Dr. Wolfgang Schmidt continues the research of his father Otto Schmidt and production of isopathic fungal remedies.

1928 The era of antibiotics begins. Alexander Fleming (1881-1955) discovers that the mold Penicillium notatum inhibits certain bacterial growth, beginning the revolutionary introduction of the drug penicillin and the age of antibiotics. (20)

1932 The Swiss physician Antoine Nebel M.D. publishes his book "Les cycles dévolution des Parasites du cancre humain" (Neuchatel, Switzerland, 1932). According to Fr. Gisevius M.D., "In 1912 Nebel began experimental research of the Micrococcus Doyen, Antimerisan from Schmidt, and Mucor racemosus. The results of his research is presented in this book." Dr. Gisevius went on to write, "In this manuscript Nebel presents the results of twenty years of research. He observed that when he combined the micrococcus Doyen with Mucor racemosus, it invaded the mycel and proceeded through a development... He gave the name of the forms that he observed Oncomyxa... by injection of cultures of Oncomyxa Type B Nebel was able to induce carcinoma and sarcoma in numerous white mice, rabbits and sheep.... At the end of his report Nebel mentions that use of a toxin developed from the cultures can be used for diagnostic and therapeutic purposes." (21) Emil Schlegel M.D. writes that the remedies manufactured by Dr. A. Nebel are both homeopathic and isopathic and have a potency of 6X or 7X. (22)

1944 Professor Guenther Enderlein (1872-1968 ) founds the company IBICA to begin the production of pharmaceutical preparations derived from molds. This was several decades after Otto and Wolfgang Schmidt, Eugene Louis Doyen, Antoine Nebel, produced and tested their own fungal remedies. It is important to emphasize that Professor Enderlein was one of the beneficiaries of the solid foundation built by other European researchers and was influenced by their ideas. He was well aware of the extensive research of these individuals in the areas of bacterial and fungal production and treatment and mentions these researchers in his works. He especially emphasizes the work of Professor Albert Adamkiewicz. (23)

1944 Selman A. Waksman (1888-1973) discovers streptomycin, an antibiotic for the treatment of the Mycobacterium tuberculosis.

1990 The book Hidden Killers by Dr. Erik Enby, Michael Sheehan and Peter Gosch is published. The research of Professor Guenther Enderlein, and the concept of isopathic-homeopathic remedies are introduced to North America in an English language book.

1997 Printing of the book Hidden Killers is halted in North America by Michael Sheehan and Peter Gosch. Because Enderlein's concept of the supposed life cycle of the fungus Mucor racemosus Fresen is questioned (and more recently has been unequivocally refuted by modern scientific research).

FOOTNOTES

1) Karl Stauffer M.D., Homoeotherapie, Hippokrates-Ve r l a g Marquardt & Cie., Stuttgart, Germany, 1950, p. 13
2) IBID, p. 123
3) Herbert Fritsche M.D., Erfahrungsheilkunde, Kabinett der Offenbaren und Geheimen Heilmester, Samuel Hahnemann und das Wagnis de Weisheit, Volume I, Karl F. Haug Verlag, Ulm/Donau, Germany, 1951-52, pp. 544-545
4) The New Encyclopaedia Britannica, Edward Jenner, Volume 6, 15th Edition, 1998, p. 530 
5) Pschyrembel Wörterbuch Naturheilkunde und alternative Heilverfahren mit Homoeopathie, Psychotherapie und Ernaehrungsmedizin, 2nd Edition, Walter de Gruyter Verlag, New York, Berlin, 1999, p. 176
6) Professor Albert Adamkiewicz, Der Forscher, Abrechnung und Entlarvung, Hannover, Germany, 1916, pp. 1-4.
7) IBID.
8) Hanns Rabe M.D., Deutsche Zeitschrift fuer Homoeopathie, Hippokrates und die Homoeopathie, Homoeopathischer Central=Verlag, Berlin, Germany, 11 Jahrgang 1932, p. 221
9) Emil Schlegel M.D., Die Krebskrankheit, Ihre Natur und Ihre Heilmittel, Hippokrates Verlag/Stuttgart/Berlin/ Zürich, 1927, p. 29
10) IBID., p.91
11) IBID., p.100
12) IBID., p. 263
13) Josef Issels M.D., Mehr Heilungen von Krebs, Helfer-Verlag E. Schwabe, Bad Homburg, Germany, 1982, pp. 70-71
14) Professor Friedrich Friedmann, Leitlinien fuer die Behandlung mit dem Friedmannschen Heil- und Schutzmittel gegen die Tuberkulose aller Formen in der Humannmedizin, Tuberkulose-Heilstoffwerk , 1933, p. 1
15) Alexander von Seld, "Dokumente zu Friedmanns kampf gegen die Tuberkulose", 1936, p. 122
16) IBID., p. 377
17) Josef Issels M.D., Mehr Heilungen von Krebs, Helfer-Verlag E. Schwabe, Bad Homburg, Germany, 1982, p. 69
18) The New Encyclopaedia Britannica, Volume 23, Medicine, 15th Edition, 1998, p. 782
19) Josef Issels M.D., Mehr Heilungen von Krebs, Helfer-Verlag E. Schwabe, Bad Homburg, Germany, 1982, p. 71
20) The New Encyclopaedia Britannica, Volume 23, Medicine, 15th Edition, 1998, p. 784
21) F r. Gisevius M.D., Deutsche Zeitschrift für Homöopathie, Herausgegeben vom Deutschen zentralverein Homöopathischer Ärzte E.G., 11 Jahrgang, 1932, Homöopathischer Central-Verlag, Berlin, 1932, pp. 193-94
22) Emil Schlegel M.D., Deutsche Zeitschrift fur Homöopathie, Herausgegben vom Duetschen zentralverein Homöopathischer Ärzte E.G., 11 Jahrg a n g , 1932, Homöopathischer Central-Verlag, Berlin, 1932, pp. 95-96
23) Professor Guenther Enderlein, Akmon, Band I, Heft 2, pp. 340-3

What Practitioners Need to Know About Enderlein’s Theory & Isopathic-Homeopathic Therapy

1) Enderlein Should Be Respected As a Dedicated Scientist and Pioneer.
Although recent molecular level studies have proven his theories incorrect, Prof. Dr. Enderlein still deserves credit for his investigations and the remedies he developed. The German scientist performed extensive work during nearly six decades of research from 1914-1968. Unfortunately, Enderlein did not have the benefit of modern scientific tools or the vast database of knowledge, including the discovery of DNA, available today. Enderlein certainly made mistakes, but they must be viewed within the context of his time.

2) Enderlein's Theory of Microbial Life Cycles Has Been Proven Scientifically Invalid.
Enderlein believed microbes such as Mucor racemosus and Aspergillus niger became more pathogenic through stages of a life cycle (virus-bacteria- fungus). Modern Proteom research and other molecular level science has shown that these supposed life cycles do not exist as described by Enderlein.

3) Isopathic Fungal Remedies Do NOT Break Down Higher Forms of Alleged Microbial Life Cycles.
Enderlein proposed that his isopathic fungal remedies copulated with higher pathogenic forms in microbial life cycles and broke them down to non-harmful forms. These life cycles do not exist, and therefore the remedies cannot work to fight disease as proposed by Enderlein.

4) Enderlein's Own Remedies Contained Phenol.
In the 1957 issue of his AKMON journal, Enderlein wrote that "a scientist ... has shown himself not able to recognize the substantial active agent of the Enderlein preparations - and this is not only the Phenol that serves to keep the remedies sterile, but also the plant protein ..." (AKMON-Bausteine zur Vollgesundheit und Akmosphie, Ibica Verlag, 1957, Volume 2, p. 335) According to Enderlein, therefore, the isopathic remedies he produced contained phenol, which apparently was an acceptable production practice at the time. Obtained from the distillation of coal tar, phenol is considered dangerous today due to its rapid corrosive action on tissues. When used carefully and properly diluted, however, phenol has been effective as a bacteriostatic agent.

5) Dr. Otto Schmidt Developed the First Isopathic Remedy Derived From Mucor Racemosus Fresen.
In 1901, Dr. Otto Schmidt extracted the fungus Mucor racemosus Fresen from cancerous tissues and developed a remedy he called Antimeristem. His idea was to create an isopathic medication that produced immunity against the cancer- causing pathogen. Enderlein founded the company IBICA in 1944 to begin the production of pharmaceutical preparations derived from molds.

6) The Isopathic Remedies Mucor racemosus and Penicillium notatum Can Be Used Together Effectively.
For years, teachers of Enderlein therapy had told practitioners not to combine Mucor racemosus and Penicillium notatum because they were part of the same life cycle and supposedly "canceled each other out." Since scientists have determined that microbial life cycles as described by Enderlein do not exist, these remedies therefore cannot neutralize one another. In fact, many practitioners today report that combining Mucor and Notatum can be highly beneficial to their patients.

7) Placing a Drop of Isopathic Remedy on a Blood Sample Does Not Enable the Observer to Confirm Whether the Remedy Is Effective.
Research has shown that this process - which has been taught by some European microscopists - is not a viable way to determine if a remedy will work for the patient.

Clinical Survey Results Show 99% of Doctors Find SulfRedox Mineral Supplement Highly Effective
By Ronald Ullmann, biochemist, Syntrion GmbH
Copyright Ronald Ullmann, 2001

A clinical survey of 354 German medical doctors and practitioners demonstrated the effectiveness of the SulfRedox mineral supplement. In summary, more than 99 percent of the participants reported high therapeutic success with their patients who used SulfRedox to help treat skin conditions, immune system disorders, frequent diarrhea, overly acidic stomach, dysbacteria, and as complementary therapy in antibiotic therapy.

The prerequisites for the study were that each medical doctor - who represented the vast majority of respondents - or health care practitioner must 1) base their findings on experience with multiple patients and 2) base their evaluations on valid clinical data using modern tools, such as stool analysis and determination of specific molecules in the feces, urine and blood. The study was designed so that the participants gained no financial benefit. The purpose of this was to prevent biased results.

Those surveyed reported using SulfRedox for treatment of the following indications and preventative therapeutic purposes: 99.15% for skin conditions; 88.7% for immune system disorders; 70.34% in frequent diarrhea; and 60.17% in overly acidic stomach conditions. In addition, doctors reported that in 88.9% of cases they used SulfRedox with antibiotic therapy to prevent negative side effects on the microflora; 68% gave it to their patients to prevent diarrhea during travel to foreign countries; and 66% of the medical doctors and practitioners indicted they use SulfRedox in combination with probiotics. Other frequent uses were for neurodermatitis, allergies, mycosis, liver disorders and rheumatism. Importantly, medical doctors and health care practitioners reported using SulfRedox for the same indications.

Results showed that 92.6 percent of the 354 participants had therapeutic success using SulfRedox in most cases and 6.5 percent reported that they had success in all cases (although it can be argued that no remedy exists that is successful in every case). Less than one percent (0.85 percent) reported success in no cases.

Questions and Answers

Q. Why are SulfRedox Tablets Manufactured with an Outer Shell and Nucleus?
A. SulfRedox tablets are comprised of two distinct parts: the outer shell and a nucleus.

The outer shell contains:

• Iron (gluconate)
• Cobalt (chloride)
• Manganese (chloride), and
• Calcium carbonicum

The nucleus consists of:

• Silicate (bentonite)
• Elemental Sulfur, and
• Vitamin C

When a patient takes SulfRedox, the outer shell quickly dissolves as the tablet enters the small intestine. The minerals contained in the outer shell help neutralize excessive acid, and provide additional benefits.

On the other hand, the tablet nucleus diffuses its active ingredients gradually as it moves along the small and large intestine to the rectum. This slow diffusion positively influences the milieu over the entire length of the intestinal tract, and is essential for therapeutic success. This process can be best compared to a field of vegetables. If only a small area is fertilized with organic substances, it will have no effect on the growth of vegetables planted in the rest of the field. For this same reason, SulfRedox' nucleus performs a step-by-step release of key ingredients over the entire length of the intestinal tract.

Q. Why Does SulfRedox Contain Four Minerals?
A. SulfRedox contains Calcium carbonicum, Iron, Cobalt and Manganese.

The Calcium carbonicum helps neutralize excessive acid not balanced by the pancreatic fluid. This step is important because the physiologic microflora in the intestines is strongly dependent on neutral or slightly alkaline conditions. In contrast, when the pH turns too acidic, non-physiologic bacteria will often take hold in the resident part of the intestinal mucosa, causing dysbiosis. For example, digestive dysfunction is often accompanied by a low pH value (acidic), which causes poor enzymatic function. Digestive enzymes function best at a neutral pH, which is necessary for proper digestion.

The minerals Iron, Cobalt and Manganese act as cofactors for the physiologic microflora. They also support the body's immune system, including granulocyte - macrophage function, and lymphocyte maturation.

Q. Why Does the Anaerobic Microflora Require a Negative Redox Potential?
A. Anaerobic microflora comprise 99.9% of physiologic microflora and benefit the human body by functioning as immune-modulators. To exist and perform their functions, the microflora require a negative redox potential, which is created by substances that readily release electrons. Therefore, it is vital that a negative redox potential is established by substances such as Vitamin C and sulfur-containing amino acids.

In contrast, oxygen readily accepts electrons, thereby creating a positive redox potential. For this reason, oxygen must be extracted from the lumen of the small and large intestine to prevent it from neutralizing the negative redox potential and establishing a positive one.

Q. How Is the Redox Potential Regulated in the Gut?
A. E.coli flourishes in a negative redox potential and extracts the residual molecular oxygen from the intestinal lumen, thus creating an oxygen- free terrain for the anaerobic microflora.

Q. How Does the Sulfur and Vitamin C Work in SulfRedox?
A. Intestinal flora bacteria use the elementary Sulfur and Vitamin C contained in SulfRedox to create a negative redox potential that - in addition to a proper pH value restored by the Calcium carbonate contained in each tablet - is an essential prerequisite for a correctly functioning physiologic microflora. In other words, conditions for the growth of healthful, physiologic microbes are created, while those for harmful, non-physiologic microbes in the gut are eliminated.

In addition, the Sulfur and Vitamin C re-establish a negative redox potential along the entire length of the intestine as they are gradually released from the tablet nucleus.

Q. How Does Bentonite Work in SulfRedox?
A. Bentonite has been shown to positively influence the mucosa by binding irritating and inflammatory molecules in the intestinal lumen and mucosa, while also balancing the intestinal pH value. As with the Vitamin C and elemental Sulfur, Bentonite is released step-by-step from the tablet nucleus over the entire length of the gut.

Bentonite also functions as dietary fiber, which positively works to enhance and accelerate stool elimination. It also acts against constipation and promotes detoxification because shortening the time required to eliminate the stool helps prevents toxins from entering or re-entering the bloodstream via the intestinal mucosa. In contrast, slow stool passage can lead to high metabolic activity in the colon microflora, resulting in metabolic products thought to be toxic and immunosuppressive to the human body.

The following positive effects have been reported for bentonite:

Binds toxic substances as secondary bile acids (metabolic products of colon microflora, especially if the diet is too rich in fats, which has been shown to be toxic to the colon)
Binds toxic aromatic compounds formed by the microflora, such as phenol from aromatic amino acids, due to a diet overly rich in protein
Binds toxins from nonphysiologic germs, including Candida infections, dysbacteria or contaminated food (aflatoxines)
Binds heavy metals

Q. Why Does SulfRedox Contain Small Amounts of Sucrose, Lactose and Binders?
A. Sucrose and lactose are important ingredients in SulfRedox because they act as the "switch" mechanisms that turn on necessary metabolic processes performed by essential intestinal bacteria. By triggering and modulating this activity, these additives also enable the key ingredients in SulfRedox to fulfill their functions.

On their surface, bacteria have receptors that react to the lactose and sucrose. These ingredients signal the bacteria that nutrients are available, which stimulates metabolic functions.As a result, specific bacteria metabolize the Sulfur to begin establishment of a negative redox potential. Three minerals contained in the outer shell of each SulfRedox tablet - cobalt, iron and manganese - further support this process. Once SulfRedox activates these microbial metabolic processes, the growth of non-physiologic microbes is inhibited and a regulation to physiologic microbes takes place. These healthful microbes can then settle and reproduce in this corrected environment.

Moreover, the small amount of binders enable the active ingredients contained in each SulfRedox tablet nucleus to be released step-by-step over the entire length of the intestinal tract.

BioTalk

In the BioMed Report lead article, Dr. Gitte Jensen, an immunologist who directs Holger NIS in Ashland, Oregon, emphasizes the need to identify microbial and non-microbial forms precisely when analyzing patients' blood. She strongly asserts that darkfield observers cannot truly know what they are looking at - or make sound therapeutic decisions for their patients - by merely viewing live blood. She points out that an observer must stain the different forms, check for DNA, and correctly link each shape with its role in the blood. Merely screening the blood provides limited information.

New research has made it more and more obvious that practitioners and non-practitioners interested in live blood analysis unfortunately are being taught outdated, unsubstantiated information about pleomorphic microbial life cycles. As Dr. Jensen explains, blood analysis cannot be based on the need to believe in an "alternative biological concept world" such as that described by Enderlein. She explains that the concept is naïve in terms of the state of modern research, the impact of the immune system, and the versatility of microbial life forms. Moreover, she points out that the shape of a so-called "symprotit" alone "DOESN'T MEAN ANYTHING!" Some non-microbial blood forms are caused by various underlying imbalances. Some forms are indeed microbes, but the observer must realize the enormity of microbial variation. Her important point is that microscopists need to scientifically identify the different particles they see in the blood and verify what biological process went wrong to create those different forms.

ENDERLEIN UNDER THE MICROSCOPE:
SHEDDING LIGHT ON DARKFIELD MICROSCOPY

In a recent Explore magazine piece and Letter to the Editor, Michael Coyle, who teaches Native Blood Analysis and sells microscopes, responded to a scientific article authored by German biochemist Ronald Ullmann ("A Modern Scientific Perspective on Prof. Dr. Enderlein's Concept of Microbial Life Cycles" - copies available from BioResource). Mr. Ullmann presented the research findings of, among others, Dr. Christopher Gerner, an assistant professor of biochemistry and researcher at the University of Vienna, Austria. Dr. Gerner used Proteom research tools and other sophisticated scientific methods to confirm that specific types of so-called "darkfield bodies" seen in the live blood were hemoglobin and albumin, and not bacterial or fungal in nature. According to Enderlein's theory of microbial life cycles, these blood forms - which the German zoologist called "symprotits" and "macrosymprotits" several decades prior to the discovery of DNA - supposedly passed through an upward development (virus-bacteriafungus) and could become pathogenic. For those willing to listen, the work of Dr. Gerner and others, including Dr. Jensen, has shown that this theory is not scientifically valid.

As a biochemist, Mr. Ullmann's qualifications include serving as president and founder of Syntrion GmbH, a German health care company specializing in research and development of diagnostic tools, blood analysis and biological medicine. He formerly worked at the worldrenowned Max Planck Institute, the preeminent institution for scientific research in Germany, where he investigated illnesses caused by impairment of the molecular transport processes in the cells.

Dr. Gerner's research and Mr. Ullmann's article focused on a specific question: Do darkfield bodies develop through a life cycle as proposed by Enderlein, and are these darkfield bodies (symprotits and macrosymprotits) bacterial in nature? The work performed by Dr. Gerner was designed to identify the molecular nature of darkfield bodies as precisely described and hand drawn by Enderlein in the AKMON series, published between 1955 and 1959, and the Immunbiologica series, published between 1946 and 1949. The AKMON and Immunbiologica issues explain Enderlein's work much more clearly than his 1925 book Bakterien Cyclogenie due to further findings he made in the years following publication.

Every scientific project starts with a defined hypothesis. The hypothesis of the work presented in the Ullmann article was that so-called darkfield bodies described by Enderlein are not bacterial phases of a microbial life cycle, but instead are non-physiologic polymerization products of blood constituents. To test the hypothesis, blood samples were taken from about 60 different patients who suffered from the same illness, and whose blood also showed darkfield bodies as described by Enderlein in the AKMON and Immunbiologica series. The samples were stained using Immunofluorescence techniques and DNA staining methods, and carefully examined for darkfield body morphologies. The results showed that blood morphologies that exactly compared to the ones described and drawn by Enderlein stained positive for globin and negative for DNA. In contrast, control samples of patient blood that failed to show darkfield bodies did not stain globin positive within the human serum and monocytes. (The existence of darkfield bodies in the human serum and within monocytes was described by Enderlein).

Mr. Coyle asks "Was the range of the study so narrow as to have not included enough individuals to represent a mycoplasma dysregulation in even one of them?" The question is irrelevant to the stated hypothesis. The work did not seek to specifically identify the presence of mycoplasma and other DNA-containing microbial forms in the patients' blood because such an investigation did not fit the hypothesis. Instead, the work focused on discovering the exact physical composition of the forms that Enderlein called symprotits and macrosymprotits. Nevertheless, in positive controls, the researchers tested the capability of the investigation method to potentially stain bacterial DNA, and the presence of mycoplasma could readily have been identified if it had helped substantiate the supposition. Moreover, the results presented in the Ullmann article followed the scientific community's internationally accepted principle that every hypothesis be addressed with suitable experiments demonstrated as successful and valid.

In this respect, it is important to mention that Mr. Coyle did not perform any scientifically recognized experiments to substantiate claims made in his Explore magazine article. In contrast, the new scientifically valid work conducted by Dr. Gerner's team and reported by Mr. Ullmann has been submitted to a peer-reviewed scientific journal, was accepted by a well-known journal in the field of alternative medicine for publication. Mr. Ullmann also verbally presented the work at a BioResource symposium last year.

Furthermore, Mr. Coyle addressed the issue of prions in an attempt to support his argument. It is well-known that Professor Stanley B. Prussiner of UCSF was awarded the Nobel Prize in 1997 for discovering prions. These are proteins that do not contain essential nucleic acid (no DNA) but are able to infect the brain and also transmit infection across different species, such as from a sheep to a cow. However, Prussiner's work does nothing to substantiate Enderlein's theory on microbial life cycles as the cause of various kinds of illnesses.

The hypothesis of the work presented in the Ullmann article was that so-called darkfield bodies described by Enderlein are not bacterial phases of a microbial life cycle, but instead are nonphysiologic polymerization products of blood constituents.

On the one hand, Enderlein proposed the existence of a colloid of plant origin native to the human body that, in its protein stage, functions as a healthy regulator in the blood. He hypothesized that under certain stimuli the healthy protein develops from its viral stage to a pathogenic bacteria, and culminates in the fungi Mucor racemosus or Aspergillus niger. Enderlein therefore believed that bacteria or fungi were the cause of various kinds of illnesses, not a protein. In stark contrast, Prussiner identified his non-DNAcontaining protein to be of endogenous origin and the specific cause of prion disease. Prussiner did NOT describe a life cycle of prions culminating in either a bacteria or the fungi Mucor racemosus and Aspergillus niger.

Mr. Coyle's argument attempts to compare apples to oranges. Under a darkfield microscope, an apple the size of an orange might appear to be the same form, yet in reality the two would be quite different. In this light, it is interesting to follow the speculation of many darkfield proponents who described darkfield bodies initially as bacteria, then next as cell wall deficient bacteria following their discovery, and now more recently as nanobacteria - all without conducting any scientifically valid experiments that could easily test their changing hypotheses.

In addition, it is important to point out that the existence of cell wall deficient bacteria, nanobacteria or fungi in human blood that may occur under certain immunedeprived conditions is by no means proof, or even an indication, of an existing microbial life cycle. As a result, we encourage Mr. Coyle to test his hypothesis or sponsor scientists that have the necessary knowledge, expertise and equipment to make a positive contribution to the interesting field of clinical microbiology. Mr. Coyle notes that he learned live blood analysis using darkfield microscopy from European instructors. Yet the fact remains that no modern, peer-reviewed, scientific evidence exists to substantiate Enderlein's theory of microbial life cycles.

On a very disappointing note, Mr. Coyle begins his article by stating that "Mr. Ullmann is the son-in-law of the family that owns SanPharma ... and should not at all be considered an unbiased or impartial source of research information." It goes without saying that Mr. Ullmann would never compromise his scientific integrity and reputation, and that the work of Dr.Gerner and Mr. Ullmann meets the highest scientific standards. It is counterproductive for Mr. Coyle or other proponents of Enderlein-type darkfield microscopy to attempt to vilify or sling mud at the work and reputation of people who are willing to bring new insights into the field. Although modern scientific approaches and highly sensitive methods may provide information that differs from long-held theories, the fresh data will contribute to the overall credibility of alternative medicine.

We all must realize that this debate is not a matter of whether Dr. Gerner's research and Mr. Ullmann's paper scatters the Enderlein concept world. The data hits the mark because it reminds us that progress in cellular and molecular biology delivers the tools to precisely unravel the validity of theories in alternative medicine. For example, such research has helped substantiate the credibility of acupuncture and some herbal medicines. Mr. Ullmann certainly serves a bridging function as a mainstream scientist who also focuses on the live blood, but his information is NOT a stand-alone phenomenon. For example, microscopists need to consider studies and published works on blood pathogens by researchers such as David Relman of the Department of Medicine, Department of Microbiology and Immunology at Stanford University, Stanford, Calif.; and Dr. Aristo Vojdani, VPofresearch and development at Immunosciences Lab Inc., Beverly Hills, Calif., who has researched mycoplasma.

The value and correctness of darkfield microscopy is questioned even in Germany. On page 58 of the Prospectus of the 34th Medizinische Woche Baden- Baden (Medicine Week) 28 October to 3 November, 2000, the following was written:

Title: DARKFIELDDIAGNOSIS AND THERAPY ACCORDING TO ENDERLEIN- What Should We Think about It?

Point of View: Analysis and an aid for the daily use in the practice
"The scene is booming! Whether the small private practice or a large biological clinic - diagnosis and treatment is complemented with a darkfield microscope. On a monitor, patients are shown their own blood. So far - so good. In addition, the patients are given an interpretation of the microscopic picture that they are shown. Where did these 'diagnosticians' learn these interpretations? From so-called 'trainers' in courses and seminars! Did anyone ever check these interpretations for their unbiased correctness? Did these 'diagnosticians ' ask the question themselvesif the learned and presented interpretation is based on scientific knowledge, wishful thinking, medical lyric or even financial calculation?"

It is common knowledge that Enderlein-type biological medicines have been available for about 50 years or so (Enderlein founded his IBICA company in 1944 and developed remedies in the 1940s and early 1950s). During that time, the field has accumulated much anecdotal evidence to support their efficacy. Until recently, practitioners were taught that isopathic fungal remedies copulated with higher, pathogenic forms of a supposed life cycle and broke them down to non-harmful particles. The work of Dr. Gerner and others has shown that these life cycles do not exist. Therefore, the fungal remedies cannot fight disease in the manner that was proposed b y Enderlein and is still being taught today! As we have emphsized for the past year, the important question is: How Do the Isopathic Remedies Actually Work? Funded partially by BioResource, research is currently being conducted by scientists in Germany and Austria to find some answers, which should be available by mid- 2002. One final point: Mr. Coyle writes that "The patterns we observe in the blood pictures still have the same meaning, ultimately, regardless of 'exactly what'you call what you are observing." This statement is particularly misleading because if the goal is to truly help patients, then practitioners or microscopists must identify precisely what they are observing in the blood. As Dr. Jensen emphasizes " If you don't know whether you are looking at a cell fragment due to oxidative stress, or a true microbe, how can anyone even think that such information would not affect how an experienced clinician will handle the case? Moreover, psychological stress that results when blood is taken from the patient can completely alter the morphologies seen. It's obvious that we need far more solid methods than darkfield microscopy when observing blood and treating patients."

FUNDING MODERN RESEARCH

During 2001, BioResource spent nearly $100,000 to help fund scientific research projects. We felt that working with accomplished scientists was important for two reasons. One, Peter Gosch and I co-authored the book Hidden Killers, which introduced many North American practitioners to Enderlein therapy beginning in 1990. Although a wide range of practitioners made it clear over the years that isopathic-homeopathic remedies - especially those produced by SanPharma - were effective, we had long wanted to find out if Enderlein's theory of microbial life cycles was science fact or science fiction. Despite the claims of some European darkfield teachers, no one seemed to have an answer supported by modern science. After all, Mr. Gosch and I had played an instrumental role in bringing Enderlein-based therapy to North America, and felt responsible to continue seeking credible answers - were Enderlein's conclusions from 1925 right or wrong? Two, we strongly believed the theory of microbial life cycles had always been the Achilles' Heel that prevented most mainstream doctors from even considering isopathic therapy. BioResource also decided that having access to modern scientific research - whether it supported or refuted the theory - would be invaluable in our attempts to introduce isopathic therapy to a larger market.

As part of this evolutionary process, we halted further printing of Hidden Killers in 1997 with the intent to update the book at some point. This decision was based on growing questions about the validity of microbial life cycles and our decision to introduce the SanPharma line of isopathic-homeopathic remedies to the U.S. market. Fortunately, Mr. Gosch had continued researching the history of isopathy - which he first began in 1986 - and discovered several volumes of the German-language HeilKunde medical books, providing new information. In addition, when the opportunity came along to work with trained scientists, BioResource was more than happy to partially fund their work and see what they discovered. Whether the researchers' concluded that Enderlein's concepts were correct or erroneous did not seem as important as actually knowing what was valid. And once the "mode of action" research currently being conducted can better explain how these remedies work in the body to fight disease, we hope this new understanding will help BioResource bring isopathic therapy to a much broader range of doctors and practitioners.

In conclusion, it's noteworthy to state that BioResource's ongoing intention is to provide solid, modern research in support of our expanding company's products and goals. Our role is not to convince anyone of what to think, but instead to examine inadequate theories and introduce new knowledge based on solid science. As more credible scientific information becomes available, microscopists and practitioners can make their own decisions about what they choose to believe, or how this fresh knowledge may help them become better healers.

THE MEANING OF "ORIGINAL"

The question of who provides authentic Enderlein remedies - or if they actually exist today - has been an area of discussion. But let's examine several facts. First of all, as Peter Gosch noted in his article, Enderlein wrote in the 1957 issue of his AKMON publication that his remedies contained phenol, which kept them sterile and functioned as a "substantial active agent." Therefore, wouldn't a truly authentic remedy need to contain phenol? Corrosive to the tissues, phenol is avoided today.

Second, just because something is called original does NOT mean it is better. For example, an original personal computer manufactured 20 years ago would be practically useless in a modern business office. Armies no longer use original muskets to fight battles, and an original telescope would be considered a mere toy today by astronomers.

Third, with the new revelations about Enderlein's erroneous research conclusions, what does it actually mean to have remedies based on an outdated and scientifically refuted theory, particularly since Enderlein thought h i s fungal remedies "copulated" with higher pathogenic forms in a life cycle and broke them apart into harmless symbionts? In reality, the new scientific research has rendered any further discussion about authentic remed i e s meaningless. In fact, most important is this: Which microbial remedies best meet the needs of patients that practitioners see everyday in their offices? As one practitioner explained, "What's important to me is which medications work most effectively for my patients today, and finding out how isopathic-homeopathic remedies actually fight disease!"

THANKS TO OUR CUSTOMERS

BioResource wishes to acknowledge its customers for their stalwart support of our company and its products. In 2000, our sales increased by about 100%, and last year they grew by another 37%. One of our ongoing objectives has been to provide North American practitioners with the most effective, highly energetic German biological medications available. We strongly believe the PEKANA and SanPharma remedies meet this high standard, and many of you have called to affirm this based on your excellent clinical results. Thank you all for enabling us to fund scientific research and continue to expand our product lines.

Hunting Down Stealth Pathogens

When viewing live, fresh blood, microscopists routinely see worm-like structures emerging from red cells, as well as elongated tubes and other particles. In the past, some Darkfield observers have labeled these forms as bacteria or Candida based on old pleomorphic theories that misidentified the particles as part of a diseasecausing life cycle. Within the past year, European and U.S. researchers have demonstrated that these erroneous concepts fail to hold up under modern scientific scrutiny.

One such group, Holger NIS in Ashland, Oregon, is examining human blood using sophisticated technology to hunt down DNA-containing particles. Led by immunologist Gitte Jensen, the scientific team also is working to distinguish bona fide microbes and pathogens from normal cellular breakdown products.

"A profound difference in thinking exists between modern mainstream science and an older biological framework proposed by Spengler, Enderlein and others as to whether a morphology observed under a microscope is alive according to current dogma, which requires the presence of nucleic acid material," Dr. Jensen explained. "We have found that many morphological forms that appear 'microbe-like' do not stand up to this definition when further analyzed. Some of the morphological forms are breakdown products from red blood cells and platelets, although their shape may appear to be 'bacterial.' Other particles most likely constitute actual cell-wall deficient life forms released during cellular break down."

According to Dr. Jensen, the term 'pleomorphic microbe' originated in mainstream medicine and means no more than changing shape, which microbes are highly capable of doing in response to stressors.

"It implies that humans have microbes in their blood that can alter metabolic activity," she said. "Our research goal is to determine if patients who suffer from chronic illnesses have a passive microbial presence or an active, pathogenic load that causes inflammation. We also hope to discover whether certain microbes can mutate by absorbing genetic material from their environment and adapt an intracellular lifestyle that damages the red blood cells, reduces oxygen transport and adversely affects the neuro-endocrine system"

THE RED BLOOD CELLAS A HIDING PLACE

Dr. Jensen's group used immuno-staining techniques, flow cytometry and fluorescence microscopy to examine the relationship between microbial forms (containing nucleic acid) and cellular elements in human blood. The researchers also looked at blood from patients who suffered from Chronic Fatigue Syndrome (CFS) and Fibromyalgia Syndrome (FMS), two examples of chronic illnesses with unknown etiology that may be linked to the presence of microbial parasites.

"Although erythrocytes are considered inert bodies that do not participate in destroying or harboring foreign invaders in healthy individuals, certain organisms are able to penetrate the red blood cell membrane," Dr. Jensen explained. "Our research showed that the red blood cells of patients with chronic illness contained overwhelming amounts of microbial parasites that we could culture and examine in the laboratory. It's important to note that none of the microbes would grow on conventional microbiological media, and would have screened negative in most clinical tests."

After drawing live, fresh blood from each patient's finger, the researchers applied three specific monoclonal markers, labeled with different colors of fluorescence: green to identify nucleic acid, orange to pinpoint erythrocyte membranes or sub-cellular particles, and red to distinguish white blood cells and platelets. The team next exposed the samples to flow cytometric analysis using an argon laser to reveal cellular origin (lineage) and complexity, including granularity, of each distinct group of particles containing nucleic acid.

"The experiment enabled us to precisely identify microbes associated with red blood cells from CFS and FMS patients, as demonstrated by the green fluorescence staining of nucleic acid," Dr. Jensen said. "The reason for fatigue in these patients could be that the bacterial parasites reduce oxygen delivery to the cell, resulting in immune dysfunction, lowered oxidative metabolism and muscle fatigue.

"In addition, we postulated that the parasites' nutritional requirements could compete with the human host and lead to dysregulation of endocrine and neuroimmune function," she concluded. "To find out, we conducted a pilot study that examined the reduction in patient symptoms, including pain, during two months of supplementation with blue-green algae high in Omega-3 essential fatty acids and immune-boosting phytochemicals. Though preliminary in nature, our research suggests that parasitized red blood cells can contribute to the disease process, and that microbial expansion will depend on the nutritional, endocrine, immune and emotional balance of the human host."